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Abstract.  The major myelin protein,  Po, has been 
shown to have decreased levels of expression and al- 
tered oligosaccharide processing after the disruption of 
Schwann cell-axon interaction.  We show here that 
lysosomal degradation of the glycoprotein shortly after 
its synthesis accounts for much of its decreased ex- 
pression in the permanently transected adult rat sciatic 
nerve, a denervated preparation  where there is no ax- 
onal regeneration or myelin assembly. If [3H]mannose 
incorporation into sciatic nerve endoneurial  slices is 
examined in the presence of the lysosomotropic agent, 
NH4CI,  a marked increase in the level of newly syn- 
thesized P0 is seen. Pulse-chase analysis of [3H]man- 
nose-labeled P0 in the presence of NI-LCI indicates 
that this increase is a consequence of inhibition of P0 
degradation that normally occurs  1-2 h after biosyn- 
thesis in the transected nerve. P0 degradation can also 
be inhibited if lysosomal function is disturbed by dila- 
tion of secondary lysosomes with L-methionine methyl 
ester.  The addition of deoxymannonojirimycin or 
swainsonine (SW), inhibitors  of oligosaccharide- 
processing mannosidases I and II,  respectively, also 
results in a decrease in P0 degradation.  This inhibition 
is presumably caused by a blockage of transport to the 
lysosomes due to altered processing of the glycopro- 
tein,  although the direct inhibition of lysosomal man- 
nosidases cannot be excluded.  In contrast to the tran- 
sected nerve, addition of NI-LC1 or SW has no effect 
on P0 levels in the crushed nerve, where myelin as- 
sembly occurs. The delivery of P0 to the lysosomes of 
the transected nerve Schwann cells does not appear to 
be triggered by the mannose-6-phosphate transport sys- 
tem involved in acid hydrolase routing.  The accumula- 
tion of a fucosylated species of P0 in the presence of 
SW indicates that the glycoprotein has progressed at 
least as far as the site of GlcNAc transferase I without 
lysosomal delivery, and thus differs from the typical 
mannose-6-phosphate-containing  glycoproteins. Fur- 
thermore,  there is no evidence of P0 phosphorylation 
either in the absence or presence of NH4C1 or SW. 
These findings indicate that the amount of Po in the 
transected nerve is regulated at the posttranslational 
level as well as at the level of transcription. 
T 
HE intracellular  sorting  of proteins from their site of 
biosynthesis to  their  final  subcellular  location  is  a 
topic that has received considerable attention.  Current 
evidence points to two general  types of protein movement: 
that involving specific recognition of newly synthesized pro- 
teins,  presumably via interaction  with receptor-like  mole- 
cules (regulated transport),  and that involving passive,  bulk 
flow that does not rely on the recognition  of the transported 
protein (constitutive  transport)  (15, 21, 44). Receptor-medi- 
ated intracellular  targeting has been directly demonstrated  in 
the delivery of hydrolases to the lysosomes (5,  16, 43). The 
observation that different  secretory proteins  transit  the en- 
doplasmic reticulum  (ER) 1 and Golgi at differing rates has 
1. Abbreviations  used in this paper: dMM, deoxymarmonojirimycin; ER, 
endoplasmic reticulum;  PGE, pore gradient  electrophoresis;  SW, swain- 
sonine. 
resulted in the hypothesis that receptors may also be involved 
in the movement of proteins through  these organelles  (54). 
While regulated  transport is generally believed to be an 
important method of targeting molecules to their proper sub- 
cellular  location,  there is a paucity of examples  of defined 
targeting  signals existing on proteins.  A classic example of 
such a recognition  system can be seen in the lysosomal en- 
zymes, where the glycoproteins are modified with phosphate 
groups on their  mannose residues and subsequently bound 
by receptors specific for mannose-6-phosphate  (5, 10, 12, 16, 
43). Poruchynsky et al. (33) have recently shown that the de- 
letion of an NH2-terminal hydrophobic region of a rotavirus 
glycoprotein normally confined to the ER results in the con- 
stitutive  secretion  of the  protein.  This  suggested  to  the 
authors that the missing sequence might have served as a sig- 
nal specifying ER localization.  Another example of a signal 
that specifies an ER destination  can be seen with the NH2- 
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secretory proteins (42).  These sequences have been shown 
to interact with a recognition particle that aids in the binding 
of the ribosome-protein complex to the ER membrane (51). 
Cleavable peptide sequences also exist on mitochondrial pro- 
teins that seem to play a role in targeting the molecules to 
the respiratory organelle (42).  Obviously, the identification 
of more recognition systems involved in intracellular trans- 
port will greatly aid in the understanding of how proteins 
reach their final destinations. 
Our laboratory has become interested in the mechanisms 
of control of intraceUular transport since we discovered that 
rat peripheral nerve Schwann cells respond to injury by alter- 
ing the levels and posttranslational processing of the major 
myelin protein,  P0  (18, 26,  27,  31). In  normal  adult  rat 
sciatic nerve, the P0 molecule is an integral myelin mem- 
brane glycoprotein  that contains a single complex type aspar- 
agine-linked oligosaccharide chain that is fucosylated and 
sulfated (20,  52).  If the adult rat sciatic nerve is crush-in- 
jured,  axonal degeneration and demyelination occur,  ulti- 
mately resulting in Schwann cell proliferation, nerve fiber 
regeneration,  and remyelination (26).  This  remyelination 
process is accompanied by increased production of P0 hav- 
ing the mature,  complex-type oligosaccharide chain (27). 
The level of  expression and the extent of  oligosaccharide pro- 
cessing of Po have been shown to be drastically changed in 
nerve injury models where there is no axonal contact and 
subsequently no myelin assembly, such as the permanently 
transected nerve and cultured neonatal Schwann cells (18, 27, 
29, 31, 32). After permanent nerve transection, the majority 
of the  Po  molecules  are  found to  contain the  immature 
ManT_sGlcNAc2 oligosaccharide  chain,  although  a  small 
amount of this intermediate species matures to the complex 
type oligosaccharide chain (27).  The accumulation of the 
high-mannose form of  the glycoprotein suggests that this spe- 
cies of the molecule is not exposed to the mannosidases in- 
volved in further processing, with slow transport of the mol- 
ecule from the ER to the Golgi being a possible cause of this 
inaccessibility to the trimming glycosidases. If a pulse-chase 
analysis of P0 is performed with transected nerve, it can be 
shown that complex type chain is  formed at a  slow rate 
(>1 h) but that the total level of P0 observed after 1-2 h of 
chase is less than the original amount of high-mannose P0 
seen during the pulse (27). This suggests  that much of the 
newly synthesized P0 is being retargeted to a site of intracel- 
lular degradation. That the transected nerve Schwann cell 
would want to rid itself of P0 is not necessarily surprising 
since the glycoprotein cannot be assembled into myelin in the 
absence of axonal contact (32). 
Two general methods exist for the degradation of endog- 
enous cellular proteins:  (a)  many  short-lived proteins  or 
proteins with structural abnormalities are degraded via the 
ATP-dependent ubiquitin pathway (3) while (b) longer-lived 
proteins seem to be degraded by lysosomal hydrolases (13). 
Since P0 is in a membrane environment after its synthesis 
on ER-bound polysomes, accessibility to the former degra- 
dative system seems unlikely. We have thus decided to exam- 
ine whether P0 is being retargeted to lysosomes and subse- 
quently degraded in the transected nerve. The results of this 
investigation, which follow, indicate that the level of P0 in 
the transected nerve is indeed regulated posttranslationally 
by lysosomal catabolism. Furthermore, this delivery to the 
lysosomes appears to occur by a method other than the typi- 
cal mannose-6-phosphate recognition system, as high-man- 
nose forms of the glycoprotein do not exit to the lysosomes. 
The lack of observable P0 phosphorylation in the transected 
nerve further implies that this modification does not play a 
role in the targeting of the glycoprotein. 
Materials and Methods 
Preparation of  Permanently Transected 
and Crushed Adult Rat Sciatic Nerve 
Sciatic nerves from male adult Sprague-Dawley rats (,o200 g) were perma- 
nently transected or crushed as described previously (26). Briefly,  rats were 
anesthetized with sodium pentobarbital, and their sciatic nerves were ex- 
posed below the sciatic notch and ligated by tying two sutures around the 
nerve trunk.  The nerve was cut between the sutures and each end was 
repositioned by  180  °  and tied to adjacent muscle. This permanent nerve 
transection prevents the reentry of axons from the proximal nerve segment 
into the distal segment and hence subsequent remyelination. Crushed in- 
jured nerves were prepared  by crushing sciatic nerves below the sciatic 
notch with a pair of fine forceps. The crushed nerves exhibit axonal regener- 
ation and remyelination of the site distal to injury, after an initial degenera- 
tion stage. After closure of the wounds, the animals were maintained for 
35-37 d. The nerves were removed for incorporation studies by anesthetiz- 
ing the animals with sodium pentobarbital and excising the distal segment 
of the sciatic nerve, including the tibial, peroneal, and sural branches. Ap- 
propriate precautions were taken for the proper care of the animals accord- 
ing to the standards established by the Animal Welfare Acts and the "NIH 
Guide for the Care and Use of Laboratory Animals" (No.  85-23 Revised 
1985).  Laboratory animal use was approved by the Mayo IACUC. 
Precursor Incorporation into 
Sciatic Nerve Endoneurial Slices 
The microdissection technique of Dyck et al.  (9) was used to remove the 
endoneurium from the perineurium and epineurium of sciatic nerves 35- 
37 d post-injury. The endoneurium from two or more nerves was sliced into 
2-ram pieces and pooled together in modified Krebs-mammalian Ringer's 
solution unless otherwise noted,  with subsequent splitting of the pooled 
slices into equal-sized portions for incubation with precursors. For incorpo- 
ration of D-[2,6-3H]mannose (54 Ci/mmol; Amersham Corp.,  Arlington 
Heights, IL), endoneurial slices were added to 100-250 ~tCi of the isotope 
in 0.5 ml of Krebs-Ringer's solution, pH 7.4, and incubated at 37°C in an 
atmosphere of 95%  02-5%  CO2  for  the times  indicated  in  the  figure 
legends. All comparative studies were incubated with equal amounts of iso- 
tope. 10 mM pyruvate was used as an energy source instead of glucose, since 
the latter binds to mannose receptors (27). In the cases where the endoneu- 
rial  slices were chased after precursor incorporation, the pulse solutions 
were replaced with Krebs-Ringer's solution containing 10 mM glucose or 
10 mM mannose and incubated for the times indicated in the figure legends. 
Incorporations carried out in the presence of inhibitors were as above, ex- 
cept that 10 mM NI-L~C1, 10 mM L-methionine methyl ester, 4 mM deoxy- 
mannonojirimycin (dMM), or 10 or 100 IxM SW were added as indicated. 
All chases and washes of samples that were incorporated with inhibitors 
contained  an equal  concentration of inhibitor.  For  the incorporation  of 
L-[5,6-3H]fucose (45  Ci/mmol;  Amersham Corp.),  3H-amino acid mix- 
ture (1 mCi/ml, Amersham Corp.), and [32P]orthophosphate (carrier free, 
285 Ci/mg; ICN Biochemicals, Inc., Irvine, CA), endoneurial slices were 
placed in 0.5 ml of Krebs-Ringer's solution containing 11.5 mM glucose and 
200-250  ~tCi of the isotopes.  Comparative studies were incubated with 
equal amounts of isotope.  Incubations were carried out as above for the 
times indicated in the figure legends either in the absence or in the presence 
of 10 mM NH4CI, 10 mM L-methionine methyl ester, or 10 or 100 ~tM SW. 
Pulse solutions were replaced before chase with Krebs-Ringer's solution 
containing 10 mM fucose or amino acid supplement (KC Biological Inc., 
Lenexa, KS) in place of [3Hlfucose and 3H-amino acid mixture, respec- 
tively. 
Endoneurial Fractionation and Solubilization 
The endoneurial slices were  fractionated according to the procedure  of 
Poduslo (26). Briefly,  the slices were homogenized in ice-cold distilled wa- 
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obtained, which was then centrifuged in an airfuge 30 ° rotor at 197,000 g 
at 4°C (model A-100; Beckman Instruments, Fullerton, CA). The superna- 
tant obtained from this centrifugation was designated as the S-I fraction. The 
resulting pellet was reconstituted in water, and SDS was added to a final con- 
centration of 1.25%.  This mixture was sonicated for 1 h  in an ultrasonic 
cleaner (model B-220; Branson Sonic Power, Inc., Danbury, CT), and then 
centrifuged as above. The supernatant from this step was the S-II fraction. 
In some cases, the endoneurial homogenates had SDS added before a first 
centrifugation. These samples were sonicated and centrifuged as above, 
with the resulting supernatant serving as a combined S-I and S-II fraction. 
Aliquots were taken from the fractions and assayed for protein according 
to the procedure of Lowry et al. (19) as modified by Hess and Lewin (14), 
using monomer BSA (Miles Laboratories, Inc., Elkhart, IN) as a standard. 
SDS-Pore Gradient Electrophoresis  (SDS-PGE) 
Endoneurial proteins were separated by SDS-PGE on a linear gradient with 
a gel concentration of 10-20% T and 1% C, using a programmable ultragrad 
gradient maker (LKB Instruments, Inc., Gaithersburg, MD) according to 
a  previously described procedure (25).  A  Tris-glycine buffer system was 
used. Proteins were solubilized in a solution containing 1% SDS (wt/vol); 
0.0625  M  "Iris, pH 6.8;  5 % 2-mercaptoethanol (vol/vol);  0.002%  bromo- 
phenyl blue (wt/vol); and  10% glycerol (vol/vol). 2-Mercaptoethanol was 
omitted from solubilizing solutions where noted in the figure legend. Pro- 
tein samples of 2.5-15 gg were subjected to electrophoresis for 2.5-3 h at 
a  constant power of 20 W  (model 3-1500 power supply; Buchler Instru- 
ments, Fort Lee, NJ). The gels and surrounding buffer were cooled to 0.5°C 
with a refrigerated circulating bath (model RTE 8; NESLAB Instruments, 
Inc., Portsmouth, NH). After electrophoresis, the gels were fixed in metha- 
nol/water/acetic acid (45:45:10).  Gels containing 3H samples were treated 
with 20%  2,5-diphenyloxazole (PPO) (wt/vol) in glacial acetic acid (34), 
followed by removal of the PPO solution and precipitation of the gel-em- 
bedded fluor with 5%  (vol/vol) glycerol. The gels containing 32p samples 
were treated with the glycerol solution immediately after fixation. Gels were 
dried on a  gel drier (model SE-1150; Hoefer Scientific Instruments, San 
Francisco, CA) before exposure to Kodak X-Omat AR or S film. Molecular 
weight estimates were determined by evaluating  the relationship log (Mr) 
versus log (%T) as described previously (2 8), except that the estimates were 
made  from fluorograms using  []4C]methylatcd  protein standards (Amer- 
sham Corp.). 
Immunoprecipitation of Po 
Immunoprecipitation of P0 was done as previously described (27).  Briefly, 
aliquots from the S-I fraction of  normal, crushed, and transected nerves (15- 
ktg samples) that had been incorporated with [32p]orthophosphate  were in- 
cubated with 7.5  p.l of rabbit anti-chick P0 gamma-globulin (kindly pro- 
vided by Dr. Catherine Mezei, Dalhousie University, Nova Scotia, Canada) 
(23) in 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCI, for 20 h at 4°C. 
The immunoprecipitate was obtained by centrifugation at 197,000 g at 4°C 
in an airfuge 30 ° rotor (model A-100; Beckman Instruments, Inc.). Precipi- 
tates were washed twice with H20 followed by centrifugation, and the pro- 
teins of the immunoprecipitate were solubilized in solubilizing solution and 
analyzed by SDS-PGE. 
Results 
Effects of Lysosomal lnhibitors on Po Levels 
To investigate whether P0 is routed to the lysosomes in the 
transected  nerve  Schwann  cell,  the  effect  of the  lysoso- 
motropic agent NI-LCI was examined.  Weak bases such as 
NH4CI inhibit hydrolases by elevating intralysosomal pH to 
a  level that is outside the range of enzyme activity (41).  In 
addition to direct inhibition of lysosomal hydrolysis, NI-hCI 
can also indirectly block catabolism by impairing receptor- 
mediated shuttling of ligands to the lysosomes by inhibiting 
receptor-ligand uncoupling (1). As seen in Fig.  1, addition of 
NH4C1 to transected nerve preparations results in a dramat- 
ic  increase in the  levels of [3H]mannose incorporated into 
newly synthesized Po in the S-I and S-II fractions.  Poduslo 
Figure 1. [3H]Mannose incorporation into permanently transected 
and crushed adult rat sciatic nerve endoneurial slices in the absence 
and presence  of NH4CI. Permanently transected and crushed en- 
doneurial  slices were incubated with  [3H]mannose for 3 h in the 
absence and presence of NH4CI, with subsequent sample prepara- 
tion to obtain S-I and S-II fractions. Each incubation was performed 
with endoneurial slices from a single nerve. 2.5 Ixg of total protein 
from each sample fraction was analyzed by SDS-PGE, followed by 
fluorography. A '4C-protein standard mixture was also included on 
the gel. The gel was exposed to Kodak X-Omat S film at  -70°C 
for 14d. 
and Yao (30) have shown that the S-I fraction contains Po in 
a  lipid environment, presumably in micelles or membrane 
vesicles formed from cellular membranes during the hypo- 
tonic homogenization of the nerve endoneurium.  The S-II 
fraction contains  the  remainder of the membrane inserted 
P0 not extracted into the S-I fraction. 
In addition  to  the  high-mannose type  species  normally 
seen in the transected nerve, a new,  faster migrating species 
of P0 with an Mr of 27,100 is  formed after the addition  of 
NH4CI. This species shows a  shift in Mr of ,~4,000  when 
analyzed by SDS-PGE in the absence of reducing agent (Fig. 
2),  a  property previously shown to he characteristic of Po 
(26,  31). The effect of NH4CI on the levels of P0 is specific 
for the transected nerve, as no increase in the levels of the 
glycoprotein are seen in crushed nerve preparations treated 
with the lysosomotropic agent (Fig.  1). 
The increase in the levels of P0 observed after the addi- 
tion of NH4C1 can be shown to be due to an inhibition  of 
P0 degradation.  As seen in Fig.  3,  pulse-chase analysis of 
[3H]mannose-labeled P0 reveals that the glycoprotein is de- 
graded  1-2 h  after synthesis in the transected nerve.  This 
degradation is prevented when NH4C1 is present in the pulse 
and chase media (Fig.  3).  Although the effect of NH4CI is 
presumably due to inhibition of lysosomal degradation (41), 
it has been shown that weak amines can also alter terminal 
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ated after NI-hC1 treatment, the lower Mr species formed in 
chase with L-methionine methyl ester shows a shift of 4 kD 
on SDS-PGE in the absence of reducing agent and can be im- 
munoprecipitated with  anti-P0  antibody (data not  shown). 
Pulse-chase analysis of 3H-amino acid-labeled P0 in the ab- 
sence of the lysosomal inhibitor reveals substantial P0 deg- 
radation within 2 h after synthesis (Fig. 4), coinciding with 
the  results  seen when  [3H]mannose is  used  as precursor. 
This indicates that the polypeptide chain and oligosaccharide 
moiety of P0 are processed in the lysosomes within a simi- 
lar time span. 
Effects of Processing lnhibitors on Po Degradation 
Addition of SW, a Golgi rnannosidase II and lysosomal ¢t-man- 
nosidase inhibitor (40, 46), also results in an increased level 
of [3H]mannose-labeled P0 in transected nerve preparations 
(Fig.  5).  The effect of SW on the intracellular level of P0 
can also be demonstrated by using a 3H-amino acid mixture 
to visualize de novo synthesis of the glycoprotein (Fig.  5). 
A dramatic increase in the amount of the glycoprotein poly- 
Figure 2.  The electrophoretic  mobility  of Po labeled  with  [3H]- 
mannose in the presence and absence of 2-mercaptoethanol (2-ME). 
2.5  Ixg of total protein from S-I fractions of transected nerve en- 
doneurial  slices labeled for 3 h with [3H]mannose in the absence 
and presence of NH4C1 were analyzed by SDS-PGE,  followed by 
fluorography. The samples were solubilized before electrophoresis 
in solubilizing buffer with or without  5 % 2-mercaptoethanol.  A 
t4C-protein standard mixture was also included on the gel, which 
was exposed to Kodak X-Omat S film at -70°C for 14 d. Intervening 
lanes were removed before photography. 
glycosylation of glycoproteins (45)  and  receptor-mediated 
endocytosis (53) through an alkalinization of the trans-Golgi 
and endosomes, respectively. To eliminate the remote possi- 
bility of any involvement of these processes in the degrada- 
tion  of P0,  a  second  method  of lysosomal inhibition  was 
used that does not depend on an increase of intralysosomal 
pH. Previous work has demonstrated that amino acid methyl 
esters selectively dilate secondary lysosomes with no effect 
on ER or Golgi structure (35). This dilation is a consequence 
of amino acid methyl ester passage into the lysosomes, fol- 
lowed by hydrolysis and subsequent trapping of the amino 
acid (8). The amino acid methyl esters cause no appreciable 
change in intralysosomal pH (8) but cause an inhibition of 
degradation solely through osmotic effects. As seen in Fig. 4, 
a  1-h incorporation of 3H-amino acids into transected nerves 
followed by  a  2-h  chase  in  the  presence of L-methionine 
methyl ester results in an inhibition of P0 degradation. The 
molecular mass of Po in the chase preparation is lower than 
that seen in the pulse, with the cause of this shift being un- 
Figure 3.  Pulse-chase  analysis of the  incorporation  of [3H]man- 
nose into permanently transected endoneurial slices in the absence 
and presence of NH4CI. 15-gg samples of total protein from com- 
bined S-I and S-II fractions were analyzed by SDS-PGE, followed 
by fluorography. Incubations of endoneurial  slices with [3H]man- 
nose were allowed to proceed for 45 min in the absence and pres- 
ence of NI-hC1, followed by chases of 60 and  120 min in the ab- 
sence and presence of the inhibitor. The migrations of ~4C-protein 
standards are indicated. The gel was exposed to Kodak X-Omat S 
film for 14 d at -70°C. Intervening lanes were removed before pho- 
tography. 
The Journal of Cell Biology, Volume 104, 1987  664 Figure  4.  Pulse-chase analysis of the incorporation of ~H-amino 
acid mixture into transected  endoneurial slices in the absence and 
presence of L-methionine  methyl ester (L-Met-OMe).  15-gg sam- 
pies of total protein from combined S-I and S-II fractions were ana- 
lyzed by SDS-PGE, followed by fluorography.  Incubations of en- 
doneurial slices were allowed to proceed for 1 h in the absence and 
presence of L-Met-OMe, followed by a 2-h chase in the absence and 
presence of inhibitor.  A ~4C-protein standard mixture was included 
on the gel, which was exposed to Kodak X-Omat AR film for 3 d 
at  -70°C. 
Figure  6.  Pulse-chase analysis  of the incorporation of [3H]man- 
nose into permanently transected  endoneurial  slices in the absence 
and presence of SW. 15-1xg  samples of total protein from combined 
S-I and  S-II fractions  were analyzed by SDS-PGE,  followed by 
fluorography.  Incubations of endoneurial  slices  were allowed  to 
proceed for 1 h in the absence and presence of SW, followed by a 
2-h chase in the absence and presence of inhibitor.  A  r'C-protein 
standard  mixture was included on the gel, which was exposed to 
Kodak X-Omat AR film for 5 d at -70°C. Intervening lanes  were 
removed before photography. 
Figure 5.  [3H]Mannose and 3H-amino acid mixture incorporation 
into permanently transected  endoneurial slices in the absence and 
presence of SW. A montage of two SDS-PGE gels is shown.  15-1tg 
samples  of total protein from combined S-I and S-II fractions of a 
6-h incorporation  of [3Hlmannose (with or without SW), and  10-1xg 
samples of  total protein from S-I and S-II fractions ofa 3-h incorpo- 
ration of 3H-amino acid mixture (with or without SW) were ana- 
lyzed. Each [3H]mannose  incorporation was done with  endoneu- 
rial slices from a single nerve. A 14C-protein standard  mixture was 
included  on the gels,  which were exposed to Kodak X-Omat AR 
film at  -70°C for 3 d. 
peptide chain can be seen in both the S-I and S-II fractions 
after  incorporation  in  the  presence  of this  inhibitor.  The 
identity of the 3H-amino acid-labeled protein seen after SW 
treatment  has  been verified as being  Po through immuno- 
precipitation with anti-P0 antibody (data not shown).  As is 
the case with NI-I4C1, addition of SW does not cause a  sig- 
nificant increase in the level of P0 in the crushed nerve (data 
not shown). 
The effect of SW on the  amount of P0,  like  that of the 
lysosomal inhibitors,  is a consequence of its prevention of Po 
degradation.  Fig. 6 demonstrates that SW blocks [3H]man- 
nose-labeled  P0  catabolism  when  it  is  included  in  pulse- 
chase media, whereas a  similar treatment in the absence of 
SW results in Po degradation after 2 h of chase. SW may be 
inhibiting P0 degradation by blocking the action of the lyso- 
somal  a-mannosidases,  as  it  has  been  demonstrated  that 
removal of the oligosaccharide moiety from glycoproteins is 
often a prerequisite to further protein catabolism (40). Alter- 
natively,  SW may inhibit  the  formation of a  species  of Po 
that is destined for degradation after it is formed subsequent 
to the action of Golgi Q-mannosidase II. This would result 
in a buildup of P0 in the cell that is not recognized as being 
targeted to the lysosomes, with this Po presumably contain- 
ing a hybrid-type oligosaccharide chain (47).  Although the 
possibility that SW exerts its effect on the lysosomes directly 
cannot be eliminated,  it can be shown that the Po generated 
in the presence of this inhibitor does progress to (and possi- 
bly beyond) the site of Golgi GlcNAc transferase I. As shown 
in Fig. 7, SW treatment results in the formation of a species 
of P0 that is fucosylated. This is in sharp contrast to the sit- 
uation observed in untreated  transected  nerve,  where only 
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endoneurial slices in the presence and absence of SW. 15-~tg sam- 
pies of total protein from combined S-I and S-II fractions were ana- 
lyzed by SDS-PGE,  followed by fluorography. Incubations of en- 
doneurial slices were allowed to proceed for 3 h in the presence and 
absence of SW, followed by a 1-h chase in the presence and absence 
of inhibitor. A  ~4C-protein standard mixture  was included on the 
gel, which was exposed to Kodak X-Omat S film for 7 d at -70°C. 
Intervening lanes were removed before photography. 
nized in the Golgi by a  receptor for mannose-6-phosphate 
(5,  43). 
The previous section revealed that P0 that accumulates af- 
ter SW treatment is fucosylated, indicating that the glycopro- 
tein  has  progressed  to  the  medial-Golgi and  has  been 
modified  by  GlcNAc  transferase  I  (38,  39).  This  finding 
strongly  suggests  that  Po  is  not  transported  by  the  usual 
mannose-6-phosphate system used in delivery of acid hydro- 
lases. These enzymes are modified while in the high-man- 
nose form (4, 22, 48, 49), before the action of GIcNAc trans- 
ferase I.  Although  it has  been reported  that  a  fraction of 
phosphorylated hydrolases can progress to the site of GlcNAc 
transferase I, this class of molecule does not bind efficiently 
to the mannose-6-phosphate receptor (49).  The possibility 
remains that  P0  is  transported  by another  ligand-receptor 
system that also relies on a phosphorylation event. To inves- 
tigate this possibility, transected nerves were incubated in the 
presence of [32p]orthophosphate, and the labeling of Po was 
examined.  Phosphate  labeling  was  also  performed  in  the 
presence of NI-I4C1 and SW to insure that the glycoprotein 
would accumulate. As seen in Fig. 9,  labeling of Po cannot 
be demonstrated in any of the transected nerve incubations. 
This lack of phosphate incorporation is in sharp contrast to 
the situation observed in normal and crush-injured nerves, 
where P0 is phosphorylated by a protein kinase after assem- 
bly into the myelin (2).  As seen in Fig.  9,  immunoprecip- 
itation  of S-I  fractions  from  nerve  slices  incubated  with 
[32p]orthophosphate  results  in  the  identification  of phos- 
phate-labeled Po in the normal and crushed nerves, but not 
in the transected nerve. The identity of the 90-kD species that 
the  small  fraction  of complex-type P0  that  forms  is  fu- 
cosylated (Fig.  7;  reference 27).  Previous studies  (38,  39) 
have documented that fucosylation does not occur before the 
action of GlcNAc transferase I, the enzyme that precedes 
Golgi mannosidase II in oligosaccharide processing (17). 
If Po degradation is occurring after the action of GIcNAc 
transferase I or mannosidase II, one would expect that any 
agent that blocks an oligosaccharide processing reaction be- 
fore these enzymes would  have an  inhibitory  effect on P0 
catabolism. This is indeed the case, as addition of the Golgi 
mannosidase I inhibitor dMM (11) prevents P0 degradation. 
Fig.  8 documents that [3H]mannose-labeled P0 formed dur- 
ing a  1-h pulse remains after 2 h of chase in the presence of 
dMM.  As shown previously and again in Fig.  8,  [3H]man- 
nose-labeled P0  is  degraded  after 2  h  of chase in  the  ab- 
sence of inhibitor. 
Analysis of Mannose-6-Phosphate 
Involvement in Po Lysosomal Delivery 
The experiments with the lysosomal and processing inhibi- 
tors  clearly demonstrate that  P0 is  normally routed to the 
lysosomes for degradation in the transected nerve. A mecha- 
nism whereby a cell directs an integral membrane (myelin) 
protein to a new cellular location (i.e., lysosomes) shortly af- 
ter  its  synthesis  is  intriguing.  It is  known  that  lysosomal 
hydrolases are targeted to their acidic organelles by the use 
of a unique receptor-ligand system. The lysosomal enzymes 
are modified with phosphate groups on mannose residues of 
their oligosaccharide chains (16), allowing them to be recog- 
Figure 8. [3H]Mannose incorporation into permanently transected 
endoneurial slices in the absence and presence of  dMM. 5- or 10-1xg 
samples of total protein from combined S-I and S-II fractions were 
analyzed by SDS-PGE, followed by fluorography. Incubations were 
allowed to proceed for 3 h in the absence and presence of dMM 
(5 ~tg analyzed), or for 1 h in the absence and presence of dMM 
followed by a 2-h chase with and without inhibitor (10 Ixg analyzed). 
A  t4C-protein standard  mixture  was included  on the gel,  which 
was exposed to Kodak X-Omat AR film for 7 d at -70°C. Interven- 
ing lanes were removed before photography. 
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transected endoneurial slices in the presence of inhibitors. 4 ~tg of 
total protein from S-I fractions and 10 Ixg of total protein from S-II 
fractions obtained after incorporation of [32P]orthophosphate  were 
analyzed by SDS-PGE. The incubations proceeded for 3 h in the 
presence of NH4CI and SW, as well as in the absence of inhibi- 
tors.  Also  shown are  anti-P0  immunoprecipitates from normal, 
crushed,  and permanently transected endoneurial slices that had 
been  incorporated  with  [32p]orthophosphate. The  migration  of 
t25I-protein standards are also  shown on the  gel, which was ex- 
posed to Kodak X-Omat AR film at  -70°C for 2 d. 
coprecipitates  with  Po  in  the  normal  and  crushed  nerves 
is unknown. That phosphorylation of P0 cannot be demon- 
strated in transected nerves even when P0 accumulates due 
to the presence of NH4C1 and  SW suggests that P0 is  tar- 
geted to the site of degradation by a mechanism that does not 
involve the use of phosphate groups. 
Discussion 
The mechanisms  whereby newly synthesized proteins are 
targeted to their final intracellular destinations have not been 
fully elucidated to date. Although a few examples of  targeting 
signals  exist,  such as  the mannose-6-phosphate groups of 
lysosomal hydrolases (5, 16, 43), the majority of  cellular pro- 
teins reach their proper destinations by unknown pathways 
and recognition systems. Earlier hypotheses that postulated 
that the oligosaccharide moieties of glycoproteins encoded 
routing signals have been proven to be invalid in many cases 
(42) since blocking glycosylation with tunicamycin, an in- 
hibitor of dolichol-linked oligosaccharide synthesis, did not 
prevent proper targeting. The roles of protein sequence and 
structure in cellular targeting have also been addressed. Re- 
cent studies that have used molecular biology techniques to 
produce altered primary  structures  in  membrane proteins 
have demonstrated that hydrophobic regions of proteins are 
necessary for proper membrane insertion (6, 37).  Likewise, 
the formation of hybrid proteins that contain a secretory pro- 
tein linked to a portion of an integral membrane protein indi- 
cates that hydrophobic sequences can anchor proteins that 
are normally soluble (7, 36,  55).  It is not clear from these 
studies  whether  these  anchoring  portions  of the  proteins 
function in targeting, or instead function solely on the basis 
of their hydrophobic interaction with lipid bilayers. Further 
demonstration of targeting or retargeting events within cells 
would expand the understanding of the processes involved in 
determining the destination of cellular components. 
The permanently transected rat sciatic nerve appears to be 
a  model system that allows the investigation of retargeting 
mechanisms. The Schwann cells of this injury model show 
dramatic cellular alterations after injury, presumably as a 
consequence of inhibition of axonal contact. Recent studies 
indicate an approximately threefold decrease in the mRNA 
levels of the major myelin glycoprotein, P0, after transec- 
tion  (18). Earlier studies demonstrated a  change in oligo- 
saccharide processing of P0 after transection (27), with the 
cells  showing  an  accumulation  of an  intermediate  high- 
mannose species of the glycoprotein. This buildup of high- 
mannose type P0 indicates that the rate of normal oligosac- 
charide processing is greatly reduced, presumably due to a 
decreased rate of transit from the ER to the Golgi. Alterna- 
tively, the altered processing may be the result of decreased 
kinetics of a Golgi mannosidase (27).  The studies presented 
here  reveal  that  the  majority of the  P0  in  the  transected 
nerve is routed to the lysosomes after biosynthesis, appar- 
ently as a means of posttranslational regulation of the level 
of this myelin component in the absence of myelin assembly. 
If transected nerve endoneurial slices are incubated for 3 h 
with  [3H]mannose  in  the  presence of the  lysosomotropic 
agent, NI-hCI, one sees a substantial increase in the level of 
newly synthesized P0. In addition to the typical high-man- 
nose form of the glycoprotein usually seen in the transected 
nerve, a new species of glycoprotein with an Mr of 27.1 kD 
is  also formed.  This species shows  a  shift in Mr of 4  kD 
when  analyzed by  SDS-PGE  in  the  absence  of reducing 
agent, a property shown to be characteristic of P0 (26,  31). 
Pulse-chase analysis reveals that the increase in P0 levels in 
the presence of NH4CI  is  a  consequence of inhibition of 
degradation of the glycoprotein that occurs  1-2 h  after its 
synthesis.  When degradation is blocked by the addition of 
NH4C1, both the high-mannose species and the 27.1-kD spe- 
cies appear after  1-2  h  of chase.  The latter species of P0 
may be the form targeted for the lysosomes or it may be a 
slightly degraded form of the glycoprotein that results from 
incomplete lysosomal inhibition by NH4C1. Definitive state- 
ments about this 27.1-kD species of P0 await further charac- 
terization of the molecule. 
Since  weak  amines  such  as  NH4C1 elevate  the  pH  of 
acidic organelles, other aspects of cellular function may be 
altered by their presence. It has been shown that trans-Golgi 
processing (45) and receptor-mediated endocytosis (53) are 
disrupted by the addition of amines. To ensure that the effect 
of NH4CI was solely due to its inhibition of lysosomal func- 
tion,  an  independent method of lysosomal disruption was 
evaluated. Amino acid methyl esters such as L-methionine 
methyl ester have been demonstrated to cause selective dila- 
tion of secondary lysosomes with no aberration of ER of 
Golgi structure (35). In addition, these agents alter lysosom- 
al  function  through  osmotic  effects,  with  no  appreciable 
change in lysosomal pH (8, 35). Thus, L-methionine methyl 
ester can be expected to inhibit lysosomal function without 
causing the pH-mediated side effects of the weak amines. As 
was  the  case  with  NHaCI,  treatment  of transected  nerve 
Brunden and Poduslo Posttranslational Regulation of Po Gene Expression  667 with L-methionine methyl ester results in the inhibition of 
Po degradation. This confirms the role of lysosomes in P0 
degradation within the transected nerve Schwann cells. 
The means by which P0 is shunted to the lysosomes in 
transected nerve is unknown, but a potential mechanism for 
P0 delivery would be  one that employed the marmose-6- 
phosphate system used in the transport of acid hydrolases to 
lysosomes (5, 10, 12, 16, 43). In this system, the acid hydro- 
lases are phosphorylated on one or two of their ctl,2-1inked 
mannose residues (4, 16, 22, 48, 49), presumably before the 
action of Golgi mannosidase I (4). These modified glycopro- 
teins are then bound by a receptor that is specific for the 
mannose-6-phosphate groups and routed to the lysosomes (5, 
43). The role of the mannose-6-phosphate system in Po tar- 
geting was investigated by using oligosaccharide processing 
inhibitors to obtain information concerning the oligosaccha- 
ride  structure of the  Po  species  transported  to  the  lyso- 
somes. Addition of the Golgi marmosidase I inhibitor dMM 
(11) resulted in an inhibition of P0 lysosomal degradation. 
This implies that Po is routed to the degradative organelles 
at a stage in oligosaccharide processing after the action of 
Golgi mannosidase I. This conclusion can be affirmed  by ex- 
amination of the effects  of the Golgi mannosidase II and 
lysosomal mannosidase inhibitor,  SW,  on Po  catabolism. 
Addition of SW to transected nerve results in the inhibition 
of P0 degradation and the accumulation of a P0 species that 
is  fucosylated,  The  inhibition of Po  degradation by  SW 
could occur in two different ways. The most obvious mecha- 
nism of inhibition is one that results from the oligosaccharide 
chain of P0 not being recognized as targeted for the lyso- 
somes because of inhibition of mannosidase II oligosaccha- 
ride processing. An alternative scheme relies on SW inhibi- 
tion of lysosomal mannosidases  that are  involved in  the 
catabolism of P0. This would result in a lysosomal buildup 
of the fucosylated glycoprotein that has been acted upon by 
GlcNAc transferase I and Golgi fucosyltransferase (38, 39). 
This latter type of inhibition would only result in a cessation 
of P0 degradation if oligosaccharide catabolism was a pre- 
requisite to polypeptide degradation (40). 
Regardless of which of these mechanisms is causing the 
inhibition of P0 catabolism by SW, the data reveal  that the 
glycoprotein that is destined for the lysosomes is  formed 
sometime after the action of Golgi GlcNAc transferase I. 
This implies that P0 has not been acted upon by the man- 
nose-6-phosphate delivery system, as the enzymes involved 
in the targeting of acid hydrolases would have modified and 
transported  the  high-mannose  oligosaccharides  that  are 
formed during  dMM  treatment and that are  temporarily 
present during SW treatment. 
Further evidence to support the contention that P0 is de- 
livered to lysosomes without using the mannose-6-phosphate 
signal is that P0 does not appear to be phosphorylated in the 
transected nerve. This observation is made when the incor- 
poration of [32P]orthophosphate  is examined either in the 
absence or presence of NI-hC1 and SW. This is in contrast 
to the situation observed in normal and crushed nerve, where 
Po phosphorylation is readily visualized after the glycopro- 
tein is assembled into myelin. Although the method of P0 
delivery to the lysosomes is not fully elucidated at this time, 
it is clear that a mechanism unlike that used by acid hydro- 
lases is functioning. It is known that other transport methods 
exist, since I-cell disease hydrolases can reach the lysosomes 
in the absence of a functioning mannose-6-phosphate system 
(24, 50). 
In summary, it appears  that the lack of axonal contact 
resulting from permanent nerve transection causes Schwann 
cells to drastically alter their cellular processing of the major 
myelin glycoprotein, P0. In addition to changes in transcrip- 
tion (18) and posttranslational processing  (27),  there is a 
rerouting of the glycoprotein from its usual site in the myelin 
to a site of degradation in the lysosomes. This targeting ap- 
pears to be a mechanism of posttranslational control of the 
level  of P0  in the  absence  of myelin assembly.  Delivery 
seems to be accomplished by exiting of the glycoprotein after 
the action of Golgi GlcNAc transferase. This degree of pro- 
cessing, when coupled to the earlier observation that there 
is a short-lived accumulation of the precursor high-mannose 
P0 (27), suggests that the species delivered to the lysosomes 
may form relatively quickly after delivery of  the glycoprotein 
from the ER to the Golgi. Further studies on this mechanism 
of targeting of the P0 molecule should allow greater under- 
standing of systems used by ceils to route proteins to specific 
sites, and may lead to an understanding of the mechanism of 
hydrolase transport in I-cell disease. 
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